News

Adams Diversified Equity Fund Reports Q1 2025 Performance Insights

Adams Diversified Equity Fund Reports Q1 2025 Performance Insights

Adams Diversified Equity Fund Investment Performance

Adams Diversified Equity Fund, Inc. (NYSE: ADX) has shared significant updates regarding its investment performance for the first quarter of 2025. Investors attentive to market trends will find the details enlightening. The Fund's total return on net asset value reported a decline of -3.9%, even with dividends and capital gains reinvested. In contrast, the S&P 500 Index and the Morningstar U.S. Large Blend category recorded a total return of -4.3% during the same timeframe.

Market Insights and Comparative Returns

The first quarter performance offers a broad perspective on the market landscape. Investors often look to contextualize these figures further. The total return on the Fund's market price also matched the -3.9% figure, suggesting that while the Fund faced challenges, it remained comparatively stable against broader market indices. Such performance metrics can aid investors in assessing their investment strategies.

Expected Shareholder Reporting

For those keen on keeping track of the Fund’s progress, the First Quarter Report to Shareholders is anticipated to be released shortly, likely providing further insights into investment strategies and performance metrics.

Annualized Comparative Returns As of March 31, 2025

Breaking down the annualized returns helps paint a clearer picture of the Fund's performance over longer periods. The latest annualized comparative returns are as follows:

• 1 Year NAV: 6.8% • 3 Year NAV: 9.4% • 5 Year NAV: 18.7% • 10 Year NAV: 13.0% These results emphasize the resilient performance of the Fund over the years, despite the recent quarterly decline.

Current Net Asset Value Details

The latest figures reveal that as of March 31, 2025, the Fund's net assets stood at approximately $2.53 billion, a decrease from about $2.83 billion from the prior year. This shift in net assets is noteworthy for investors who monitor the overall health and liquidity of their investment holdings.

Share Count and Value Analysis

As for the shares outstanding, the total is reported at 118,862,758, yielding a net asset value per share of $21.28, down from $22.81 a year ago. Such fluctuations can indicate market volatility and a need for strategic adjustments.

Top Ten Equity Holdings Overview

Understanding where the Fund allocates its investments can help investors gauge its future performance. The top ten equity holdings as of March 31, 2025, include major companies in the tech sector, illustrating the Fund’s strategic focus. Here is a snapshot of these holdings:

• Apple Inc.: 7.4% • Microsoft Corporation: 6.5% • NVIDIA Corporation: 5.7% • Amazon.com, Inc.: 4.3% • Alphabet Inc. Class A: 3.3% • Meta Platforms, Inc. Class A: 2.9% • JP Morgan Chase & Co.: 2.3% • Adams Natural Resources Fund, Inc.: 2.2% • Visa Inc. Class A: 1.9% • Broadcom Inc.: 1.8%

This total represents 38.3% of the Fund’s net assets, showcasing a heavy investment in technology and finance sectors.

Sector Weightings as of March 31, 2025

Further insights can be gained by examining sector weightings, which help investors understand the sectors that the Fund primarily invests in:

• Information Technology: 29.5% • Financials: 14.3% • Health Care: 11.3% • Consumer Discretionary: 10.7% • Communication Services: 9.1% • Industrials: 7.7% • Consumer Staples: 6.4% • Energy: 3.9% • Utilities: 2.4% • Real Estate: 2.2% • Materials: 1.8%

This diversification across sectors could be indicative of the Fund's strategy to mitigate risk while targeting profitable investment opportunities.

About Adams Funds

Founded in 1929, Adams Funds has a long-standing reputation for helping investors achieve their financial objectives. The Fund operates through two closed-end funds: Adams Diversified Equity Fund, Inc. (NYSE: ADX) and Adams Natural Resources Fund, Inc. (NYSE: PEO). With a focus on stability and reliable dividends, the Funds are actively managed by a dedicated team aiming to deliver consistent returns to shareholders while navigating various market cycles.

The commitment to providing a minimum annual distribution rate of 8% of NAV serves as a cornerstone of their investment philosophy, appealing particularly to long-term shareholders seeking steady income streams. Investors can purchase shares through brokers or directly from the Funds' transfer agent.

Frequently Asked Questions

What was the total return on the Fund’s market price for Q1 2025?

The total return on the Fund’s market price for the first quarter of 2025 was -3.9%.

How does the Fund's performance compare to the S&P 500?

The Fund underperformed compared to the S&P 500, which recorded a total return of -4.3% during Q1 2025.

What is the net asset value per share?

The net asset value per share as of March 31, 2025, is $21.28.

What are the top equity holdings in the Fund?

The top equity holdings include Apple Inc., Microsoft Corporation, and NVIDIA Corporation, among others.

Where can I find more information about Adams Funds?

Additional information about Adams Funds can be found on their official website, adamsfunds.com, or by contacting them directly.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 76

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 110

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 43

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Dental Exams Are Routine Until They Catch Something Early

Updated Category News Views 60

A mouth can look perfectly fine right up until it does not. That is the unglamorous value in the dental exam and X-rays visit described by Dr. Eric Runyon of Smiles Unlimited in Belton, Missouri: it is a structured look for trouble before pain, swelling, or a cracked tooth forces the issue. Nobody throws a parade for preventive care, but waiting for symptoms has a habit...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 148

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
es